EI

272.3

+2.25%↑

SAN

79.06

-1.25%↓

MRK1

106.8

-0.56%↓

SHL.DE

47.68

-0.42%↓

ARGX

640

-0.37%↓

EI

272.3

+2.25%↑

SAN

79.06

-1.25%↓

MRK1

106.8

-0.56%↓

SHL.DE

47.68

-0.42%↓

ARGX

640

-0.37%↓

EI

272.3

+2.25%↑

SAN

79.06

-1.25%↓

MRK1

106.8

-0.56%↓

SHL.DE

47.68

-0.42%↓

ARGX

640

-0.37%↓

EI

272.3

+2.25%↑

SAN

79.06

-1.25%↓

MRK1

106.8

-0.56%↓

SHL.DE

47.68

-0.42%↓

ARGX

640

-0.37%↓

EI

272.3

+2.25%↑

SAN

79.06

-1.25%↓

MRK1

106.8

-0.56%↓

SHL.DE

47.68

-0.42%↓

ARGX

640

-0.37%↓

Search

Laboratorios Farmaceuticos Rovi SA

Avatud

SektorTervishoid

59.6 -0.5

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

59.45

Max

60.4

Põhinäitajad

By Trading Economics

Sissetulek

3.9M

27M

Müük

4.8M

160M

P/E

Sektori keskmine

23.07

35.664

Aktsiakasum

0.423

Dividenditootlus

1.56

Kasumimarginaal

16.767

Töötajad

2,188

EBITDA

4.2M

35M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+33.53% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

1.56%

3.12%

Järgmine tulemuste avaldamine

6. nov 2025

Turustatistika

By TradingEconomics

Turukapital

235M

3.1B

Eelmine avamishind

60.1

Eelmine sulgemishind

59.6

Uudiste sentiment

By Acuity

56%

44%

327 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. sept 2025, 22:39 UTC

Omandamised, ülevõtmised, äriostud

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15. sept 2025, 16:43 UTC

Suurimad hinnamuutused turgudel

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15. sept 2025, 16:42 UTC

Suurimad hinnamuutused turgudel

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15. sept 2025, 16:35 UTC

Suurimad hinnamuutused turgudel

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15. sept 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. sept 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15. sept 2025, 23:34 UTC

Market Talk

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15. sept 2025, 22:48 UTC

Market Talk

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15. sept 2025, 22:12 UTC

Omandamised, ülevõtmised, äriostud

CSL Expects Commercial Launch in 2029

15. sept 2025, 22:12 UTC

Omandamised, ülevõtmised, äriostud

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15. sept 2025, 22:11 UTC

Omandamised, ülevõtmised, äriostud

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15. sept 2025, 22:11 UTC

Omandamised, ülevõtmised, äriostud

CSL to Have Right to Exercise Option Based on Phase 3 Data

15. sept 2025, 22:10 UTC

Omandamised, ülevõtmised, äriostud

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15. sept 2025, 21:16 UTC

Omandamised, ülevõtmised, äriostud

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15. sept 2025, 21:16 UTC

Omandamised, ülevõtmised, äriostud

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15. sept 2025, 21:15 UTC

Omandamised, ülevõtmised, äriostud

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15. sept 2025, 21:14 UTC

Omandamised, ülevõtmised, äriostud

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15. sept 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. sept 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15. sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. sept 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15. sept 2025, 19:14 UTC

Market Talk

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15. sept 2025, 18:16 UTC

Market Talk

Gold Powers to New High -- Market Talk

15. sept 2025, 18:05 UTC

Market Talk

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15. sept 2025, 17:50 UTC

Omandamised, ülevõtmised, äriostud

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15. sept 2025, 17:10 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. sept 2025, 17:10 UTC

Market Talk

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15. sept 2025, 16:52 UTC

Market Talk

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15. sept 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

15. sept 2025, 16:20 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Laboratorios Farmaceuticos Rovi SA Prognoos

Hinnasiht

By TipRanks

33.53% tõus

12 kuu keskmine prognoos

Keskmine 80.85 EUR  33.53%

Kõrge 90 EUR

Madal 71.7 EUR

Põhineb 2 Wall Streeti analüütiku instrumendi Laboratorios Farmaceuticos Rovi SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

2

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

51.1 / N/AToetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

327 / 371 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat